

Agenda

Title of Meeting	Somerset Prescribing Forum
Date	23 rd May 2018
Time	14.30
Venue	Meeting Room 1, Wynford House, Yeovil BA22 8HR

Please notify Catherine Henley if you are unable to attend at: [REDACTED]

Agenda Number	Item Description and Action	Item Presenter / Details of Enclosed Papers
1	Introductions:	
2	Apologies for absence:	
3	Declarations of interest	See last page of agenda
4	Minutes of the meeting on 14 th March 2018	Attachment 4
	• Review of action points	
	PART 1 – Items for discussion or decision	
5	Matters Arising	
5.1	An audit on Antipsychotic prescribing in people with learning disabilities	Steve DuBois
5.2	Final Draft Single Shared Care Guideline for Disease Modifying Drugs	Attachment 5.2
5.3	Antipsychotic Shared Care Guidance update	Attachment 5.3
5.4	Opicapone outcomes	Dr. A Goff
6	Other Issues	
6.1	NHS Counter Fraud Authority: Management and control of prescription forms: A guide for prescribers and health organisations	Attachment 6.1
6.2	Support pharmacy staff in acute care to manage patients with mental health and/or substance misuse issues	Attachment 6.2a & b
6.3	Polypharmacy Guidance	Attachment 6.3a & b
6.4	Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness The BMJ	See link
6.5	Metoject revised pricing	Attachment 6.5a & b
7	Formulary Applications	
7.1	Testogel (Testosterone) 16.2mg/g gel in a Pump Formulation, Besins Healthcare. 1x30g pump £31.11	Attachment 7.1 See Link to SPC
7.2	POWERbreathe Medic device, POWERbreathe Int LTD 1x device £17.90 Inspiratory Muscle Training Device	Attachment 7.2
7.3	Fusacomb Easyhaler DPI (salmeterol/fluticasone) Orion Pharma	See links to SPCs

	50micrograms/250microgram £21.50 x 60 dose 50micrograms/ 500micrograms £26.99 x 60 dose Therapeutic Indications <u>Asthma in adults and children over 12 years</u> <u>Chronic Obstructive Pulmonary Disease (COPD)</u>	
7.4	Levosert IUD	See link
8	DTC decisions and other reports	
8.1	Somerset Partnership Mental Health D&TC – Last Meeting 13/03/18 – Minutes not received	
8.2	YDH D&TC – Has been replaced by Medicines Committee meetings. Last meeting: 28/03/18 – Minutes already received	
8.3	T&ST D&TC – Last meeting 4/05/18 – Minutes not yet received	
8.4	T&S Antimicrobial Prescribing Group – Last meeting 14/02/18 postponed to 07/03/18 – Draft Minutes received	
8.5	RUH Bath D&TC – Last meetings 12/04/18 – Minutes received	
8.6	BNSSG D&TC — Last meeting 28/03/18 – Minutes not received	
8.7	BNSSG Joint Formulary Group – Last meeting 10/04/18 – Minutes received	
8.8	LPC report	
8.9	RMOC function on SPS website	See Link
	Part 2 – Items for Information or Noting	
9	NICE Guidance (see April Link and May Link for guidance by month)	See Link
	NICE Technology Appraisals	
9.1	[TA510] Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	See Link
9.2	[TA511] Brodalumab for treating moderate to severe plaque psoriasis	See Link
9.3	[TA512] Tivozanib for treating advanced renal cell carcinoma	See Link
9.4	[TA513] Obinutuzumab for untreated advanced follicular lymphoma	See Link
9.5	[TA514] Regorafenib for previously treated advanced hepatocellular carcinoma	See link
9.6	[TA515] Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen	See Link
9.7	[TA516] Cabozantinib for treating medullary thyroid cancer	See Link
9.8	[TA517] Avelumab for treating metastatic Merkel cell carcinoma	See Link
9.9	[TA518] Tocilizumab for treating giant cell arteritis	See Link
9.10	[TA519] Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	See Link
9.11	[TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy	See Link
10	NICE Clinical Guidance	
10.1	[NG87] Attention deficit hyperactivity disorder: diagnosis and	See Link

	management -New	
10.2	[NG88] Heavy menstrual bleeding: assessment and management -New	See Link
10.3	[NG89] Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism -New	See Link
10.4	[NG90] Physical activity and the environment -New	See Link
10.5	[NG91] Otitis media (acute): antimicrobial prescribing -New	See Link
10.6	[NG92] Stop smoking interventions and services -New	See Link
10.7	[NG93] Learning disabilities and behaviour that challenges: service design and delivery -New	See Link
10.8	[NG94] Emergency and acute medical care in over 16s: service delivery and organisation -New	See Link
10.9	[NG95] Lyme disease -New	See Link
10.10	[NG96] Care and support of people growing older with learning disabilities -New	See Link
10.11	[CG90] Depression in adults: recognition and management -Update MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby.	See Link
10.12	[CG137] Epilepsies: diagnosis and management -Update MHRA advice on valproate	See Link
10.13	[CG173] Neuropathic pain in adults: pharmacological management in non-specialist settings -Update MHRA advice on valproate	See Link
10.14	[CG185] Bipolar disorder: assessment and management -Update MHRA advice on valproate	See Link
10.15	[CG192] Antenatal and postnatal mental health: clinical management and service guidance -Update MHRA advice on valproate	See Link
11	Specialist Commissioning	
	None this month	
12	PBR excluded drug monitoring	
12.1	T & S	To be tabled
12.2	Yeovil	To be tabled
13	Biosimilars	
13.1	Biosimilar Adalimumab	Attachment 13.1
14	Horizon Scanning	
14.1	NICE forward planner - for noting	See Link
15	Safety items, NPSA Alerts and Signals	
15.1	MHRA Drug Safety Update April 18	See Links
15.2	EMA New measures to avoid valproate exposure in pregnancy endorsed	Attachment 15.2

15.3	PSA: Risk of death or severe harm from inadvertent intravenous administration of solid organ perfusion fluids	See Link
15.4	PSA: Resources to support the safe adoption of the revised National Early Warning Score (NEWS2)	See Link
16	BNF Changes	
	BNF March & April 18 Update	See Link
17	Any other business	
	Date of Next Meetings:	
	Wednesday 18 th July 2018	MR2, Wynford House
	Wednesday 19 th September 2018	MR2, Wynford House
	Wednesday 21 st November 2018	MR2, Wynford House

Distribution (as of January 2018)

Dr Clare Barlow
Jon Beard
Dr Rosemary Brook
Steve Du Bois
Orla Dunn
Shaun Green

Liz Harewood
Catherine Henley
Michael Lennox
Sam Morris
Michaela Nock
Jean Perry

Andrew Prowse
Dr Geoff Sharp
Zoe Talbot-White
Caroline Taylor
Donna Yell

For Information

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Karen Taylor

Somerset CCG Prescribing Forum – Declaration of Interests (September 2017)

Name	Position	Interests Declared
Dr Clare Barlow	Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS Foundation Trust	Occasional sponsored educational meetings.
Jon Beard	Chief Pharmacist, Taunton & Somerset NHS Foundation Trust	None declared
Steve DuBois	Somerset Partnership Chief Pharmacist	Employee of Somerset Partnership NHS Foundation Trust Pharmacy Management network team member. Lister House Surgery management has been taken over by Somerset Partnership. 3/17 - Took part in a group to develop a pharmacy education programme on Diabetes, it had no promotional content but was funded by the Novo Nordisk.

Dr Orla Dunn	Consultant, Public Health, Somerset County Council	Director and part owner of Health Behaviour Research Ltd Partner is director of Power System Consulting Ltd
Shaun Green	Head of Medicines Management	16/17 none declared
Liz Harewood	Somerset Partnership Representative	Occasional attendance at pharmaceutical industry supported meetings & training. Will advise if related to any medicine under discussion.
Catherine Henley	Medicines Manager, NHS Somerset CCG	Practice Pharmacist at Wellington Medical Centre and Work as a locum community pharmacist. Ad hoc Consultancy work
Sam Morris	Medicines Manager, NHS Somerset CCG	Zero hour contract pharmacist for Boots.
Michaela Nock	Deputy Clinical Pharmacy Manager, Yeovil NHS Foundation Trust	Occasional lunchtime meetings sponsored by pharmaceutical companies providing lunch
Jean Perry	Commissioning Manager, NHS Somerset CCG	None declared
Andrew Prowse	Chief Pharmacist, Yeovil NHS Foundation Trust	Chief Pharmacist, Dorset county hospital NHS Foundation Trust Occasional attendance at pharmaceutical industry support meetings. Involved in occasional market research related to pharmaceutical industry. Member of National reference Group for England for 'Pharmacy Management'
Dr Geoff Sharp	Chair	GP Partner, The Park Medical Partnership, PMS Practice The Park Medical Practice is a provider of medical services to Shepton Mallet Community Hospital (under contract to Somerset Partnership NHS Foundation Trust) Provides Out-of-Hours services for Somerset Doctors and Urgent Care (SDUC) Member of Somerset Primary Healthcare
Zoe Talbot-White	Pharmacy Technician, NHS Somerset CCG	None declared
Caroline Taylor	Pharmacy Technician, NHS Somerset CCG	None declared
Donna Yell	Pharmacoeconomic s lead, Yeovil NHS Foundation Trust	Occasional lunchtime meetings sponsored by pharmaceutical companies providing lunch. Occasional meetings with reps to discuss new medicines.